AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) ...
Fierce Pharma

AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde

Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
Pharmabiz

AbbVie seeks US FDA approval for Skyrizi subcutaneous induction for adults with moderately to severely active Crohn's disease

AbbVie seeks US FDA approval for Skyrizi subcutaneous induction for adults with moderately to severely active Crohn's disease: North Chicago, Illinois Wednesday, April 29, 2026, 1 ...
Fierce Biotech

Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...
Medscape

Pediatric Plaque Psoriasis Treatment Set to Expand in Europe

European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.
Healthline

Skyrizi: How It Works

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...
SFGate

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

AbbVie, Inc. ABBV announced that the European Commission (EC) approved its drug Skyrizi (risankizumab) for a second indication, which is active psoriatic arthritis. The EC approval is for subcutaneous ...